MT. OLIVE, NJ-Just when you thought the M&A activity had quieted down within New Jersey’s pharma industry, another big deal comes along. North Chicago, IL-based Abbott Labs has acquired Knoll Pharmaceuticals, based here, from BASF AG, Germany’s biggest chemical concern. The price tag in the all-cash deal is $6.9 billion.

The impact on Knoll’s New Jersey and worldwide operations isn’t immediately clear but figures to sort itself out between now and the end of the first quarter of ’01, when the contract is slated to be completed pending regulatory review. Knoll has almost 800 employees at its Mt. Olive HQ, plus another 200 at a manufacturing facility in nearby Whippany, NJ. Worldwide, the company has 10,700 employees, according to a company insider.

The two companies are expected to put together an integration plan over the next few months, according to the Knoll executive, “but Abbott will ultimately make the decisions.”

And industry observers generally agree that the move is a good one for all concerned. Abbott Labs, for example, has mostly been a healthcare products producer longing to be a bigger player in the pharma business. The company had attempted to buy Alza, a drug company, last year. Abbott will now gain some of that clout with the acquisition of Knoll, which has been rolling out such products as the promising new rheumatoid arthritis drug, D2E7; Meridia, an obesity treatment drug; and Synthroid, which is used to treat thyroid problems.

D2E7 alone is projected to have potential sales of more than $1 billion. Knoll’s overall 2000 sales are projected in the $2.1 billion range, according to the spokesperson.

Abbott, with its marginal pharma activities, and Knoll, a mid-sized company, are expected to be better able to compete in this age of mega mergers and pharmaceutical giants. BASF, meanwhile, has been longing to return exclusively to its roots in specialty chemicals, including pesticides, herbicides, oils and gasses. As a stand-alone, or as a mismatched component of BASF, Knoll was considered too small to compete despite its recent record of innovation.

Want to continue reading?
Become a Free ALM Digital Reader.

Once you are an ALM digital member, you’ll receive:

  • Unlimited access to GlobeSt and other free ALM publications
  • Access to 15 years of GlobeSt archives
  • Your choice of GlobeSt digital newsletters and over 70 others from popular sister publications
  • 1 free article* every 30 days across the ALM subscription network
  • Exclusive discounts on ALM events and publications

*May exclude premium content
Already have an account?


© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.


Join GlobeSt

Don't miss crucial news and insights you need to make informed commercial real estate decisions. Join now!

  • Free unlimited access to's trusted and independent team of experts who provide commercial real estate owners, investors, developers, brokers and finance professionals with comprehensive coverage, analysis and best practices necessary to innovate and build business.
  • Exclusive discounts on ALM and GlobeSt events.
  • Access to other award-winning ALM websites including and

Already have an account? Sign In Now
Join GlobeSt

Copyright © 2024 ALM Global, LLC. All Rights Reserved.